Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Free Cash Flow (2016 - 2025)

BioCorRx's Free Cash Flow history spans 16 years, with the latest figure at -$634447.0 for Q3 2025.

  • For Q3 2025, Free Cash Flow fell 77.45% year-over-year to -$634447.0; the TTM value through Sep 2025 reached -$1.7 million, down 22.76%, while the annual FY2024 figure was -$1.1 million, 40.85% up from the prior year.
  • Free Cash Flow for Q3 2025 was -$634447.0 at BioCorRx, down from -$126499.0 in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$126499.0 in Q2 2025 and bottomed at -$1.3 million in Q2 2021.
  • The 5-year median for Free Cash Flow is -$449576.0 (2022), against an average of -$525344.9.
  • The largest annual shift saw Free Cash Flow plummeted 147.93% in 2021 before it skyrocketed 73.72% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at -$647624.0 in 2021, then surged by 30.58% to -$449576.0 in 2022, then dropped by 18.74% to -$533836.0 in 2023, then surged by 53.7% to -$247170.0 in 2024, then crashed by 156.68% to -$634447.0 in 2025.
  • Per Business Quant, the three most recent readings for BICX's Free Cash Flow are -$634447.0 (Q3 2025), -$126499.0 (Q2 2025), and -$689623.0 (Q1 2025).